Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and TACE for MVI in HCC After Radical Resection
NCT02537158Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: recurrence-free survival at 36 months. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02537158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537158.